$8.16 Billion is the total value of Baker Brothers Advisors's 107 reported holdings in Q2 2014. The portfolio turnover from Q1 2014 to Q2 2014 was 16.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GEVA | Buy | Synageva Biopharma Corp. | $1,117,213,000 | +26.5% | 10,660,432 | +0.1% | 13.68% | +21.9% |
| PCYC | Buy | Pharmacyclics Inc. | $860,458,000 | -1.7% | 9,591,546 | +9.8% | 10.54% | -5.3% |
| SGEN | Buy | Seattle Genetics, Inc. | $859,562,000 | -9.0% | 22,472,229 | +8.4% | 10.53% | -12.3% |
| INCY | Buy | Incyte Corp. | $837,883,000 | +5.5% | 14,845,559 | +0.1% | 10.26% | +1.7% |
| Salix 2.75% 5/15/15conv bonds | $585,836,000 | +19.1% | 219,440,000 | 0.0% | 7.18% | +14.8% | ||
| ACAD | Acadia Pharmaceuticals Inc. | $462,676,000 | -7.2% | 20,481,442 | 0.0% | 5.67% | -10.5% | |
| GHDX | Buy | Genomic Health Inc. | $374,144,000 | +4.0% | 13,654,902 | +0.0% | 4.58% | +0.3% |
| Incyte Corporation Notes 1.25% 11/15/2020 144Aconv bonds | $371,605,000 | +6.0% | 274,500,000 | 0.0% | 4.55% | +2.2% | ||
| Incyte Corporation Notes 0.375% 11/15/2018 144Aconv bonds | $345,981,000 | +5.9% | 259,000,000 | 0.0% | 4.24% | +2.0% | ||
| Incyte Corporation Notes 4.75% 10/1/2015 144Aconv bonds | $259,336,000 | +5.5% | 40,446,000 | 0.0% | 3.18% | +1.7% | ||
| ITMN | Buy | Intermune Inc. | $208,515,000 | +44.0% | 4,722,869 | +9.2% | 2.55% | +38.8% |
| Intermune Inc Notes 2.5% 12/15/17conv bonds | $141,190,000 | +30.9% | 41,000,000 | 0.0% | 1.73% | +26.1% | ||
| BCRX | Buy | Biocryst Pharmaceuticals Inc. | $138,859,000 | +123.7% | 10,890,872 | +85.6% | 1.70% | +115.6% |
| BMRN | Buy | Biomarin Pharmaceuticals | $118,711,000 | -7.6% | 1,908,230 | +1.3% | 1.45% | -11.0% |
| XOMA | Buy | Xoma Corp. | $105,873,000 | -11.9% | 23,065,972 | +0.0% | 1.30% | -15.1% |
| AVNR | Buy | Avanir Pharmaceuticals | $104,670,000 | +392.6% | 18,558,487 | +220.5% | 1.28% | +374.8% |
| Gilead 1.625% 5/1/16conv bonds | $78,358,000 | +17.1% | 21,500,000 | 0.0% | 0.96% | +12.9% | ||
| VNDA | Sell | Vanda Pharmaceuticals, Inc. | $70,741,000 | -2.1% | 4,372,153 | -1.7% | 0.87% | -5.7% |
| Biomarin Pharmaceuticals Notes 1.875% 4/23/2017conv bonds | $70,511,000 | -8.6% | 22,898,000 | 0.0% | 0.86% | -11.8% | ||
| ANAC | Buy | Anacor Pharmaceuticals | $57,588,000 | -7.0% | 3,248,043 | +4.9% | 0.70% | -10.4% |
| Sell | Medivation 2.625% 4/1/17conv bonds | $55,324,000 | -1.7% | 34,720,000 | -12.1% | 0.68% | -5.2% | |
| DYAX | Buy | Dyax Corp. | $54,540,000 | +139.9% | 5,681,237 | +124.4% | 0.67% | +131.1% |
| RPRX | Repros Therapeutics | $48,071,000 | -2.5% | 2,778,654 | 0.0% | 0.59% | -6.1% | |
| MRTX | Mirati Therapeutics Inc. | $47,601,000 | +4.9% | 2,380,074 | 0.0% | 0.58% | +1.0% | |
| QCOR | Sell | Questcor Pharmaceuticals, Inc. | $46,245,000 | -0.8% | 500,000 | -30.3% | 0.57% | -4.4% |
| CERS | Buy | Cerus | $42,523,000 | +4.8% | 10,246,591 | +21.2% | 0.52% | +1.0% |
| DSCI | Derma Sciences | $40,889,000 | -8.8% | 3,537,137 | 0.0% | 0.50% | -12.1% | |
| Intermune Inc Notes 5% 3/1/15conv bonds | $39,842,000 | +30.2% | 16,860,000 | 0.0% | 0.49% | +25.4% | ||
| VSAR | New | Versartis Inc. | $34,935,000 | – | 1,245,889 | +100.0% | 0.43% | – |
| CLVS | Buy | Clovis Oncology | $32,847,000 | -10.5% | 793,221 | +49.7% | 0.40% | -13.9% |
| HRTX | Buy | Heron Therapeutics, Inc. | $32,128,000 | +6.5% | 2,607,784 | +20.3% | 0.39% | +2.9% |
| ACOR | Sell | Acorda Therapeutics, Inc. | $30,544,000 | -19.4% | 906,091 | -9.4% | 0.37% | -22.4% |
| Salix 1.5% 3/15/19conv bonds | $29,447,000 | +16.4% | 15,000,000 | 0.0% | 0.36% | +12.5% | ||
| HALO | Sell | Halozyme Therapeutics Inc. | $27,428,000 | -62.1% | 2,776,143 | -51.3% | 0.34% | -63.5% |
| GILD | Sell | Gilead Sciences Inc. | $21,234,000 | -46.1% | 256,108 | -53.9% | 0.26% | -48.1% |
| ARWR | Buy | Arrowhead Research Corp. | $20,475,000 | +70.3% | 1,430,802 | +95.4% | 0.25% | +64.1% |
| TGTX | TG Therapeutics | $20,291,000 | +36.1% | 2,160,965 | 0.0% | 0.25% | +31.1% | |
| XNPT | Xenoport | $19,485,000 | -6.6% | 4,034,112 | 0.0% | 0.24% | -9.8% | |
| PGNX | Progenics Pharmaceuticals, Inc. | $19,179,000 | +5.4% | 4,449,797 | 0.0% | 0.24% | +1.7% | |
| New | Salix Pharmaceuticals Ltd Put 115 July 14 | $15,431,000 | – | 125,100 | +100.0% | 0.19% | – | |
| AEGR | Sell | Aegerion Pharmaceuticals | $13,283,000 | -44.0% | 413,922 | -19.5% | 0.16% | -45.8% |
| OMER | Omeros Corp. | $13,116,000 | +44.2% | 753,804 | 0.0% | 0.16% | +38.8% | |
| Biomarin Pharmaceuticals Notes 0.75% 10/15/2018conv bonds | $12,895,000 | -5.9% | 12,500,000 | 0.0% | 0.16% | -9.2% | ||
| KYTH | Kythera Biopharmaceuticals | $11,943,000 | -3.5% | 311,255 | 0.0% | 0.15% | -7.0% | |
| AQXP | Aquinox Pharmaceuticals, Inc. | $11,355,000 | -26.4% | 1,211,851 | 0.0% | 0.14% | -29.1% | |
| QLTI | QLT Inc. | $9,492,000 | +11.2% | 1,535,863 | 0.0% | 0.12% | +6.4% | |
| AGIO | Agios Pharmaceuticals | $9,159,000 | +17.0% | 199,893 | 0.0% | 0.11% | +13.1% | |
| NBIX | Buy | Neurocrine Biosciences, Inc. | $8,230,000 | +14.1% | 554,590 | +23.8% | 0.10% | +9.8% |
| OSIR | Buy | Osiris Therapeutics Inc. | $7,976,000 | +68.0% | 510,606 | +41.2% | 0.10% | +63.3% |
| SGMO | Sangamo Biosceiences, Inc. | $7,983,000 | -15.5% | 522,764 | 0.0% | 0.10% | -18.3% | |
| INFI | Infinity Pharmaceuticals Inc. | $7,950,000 | +7.1% | 624,050 | 0.0% | 0.10% | +3.2% | |
| BLUE | Bluebird Bio Inc. | $7,647,000 | +69.6% | 198,260 | 0.0% | 0.09% | +64.9% | |
| AERI | Aerie Pharmaceuticals | $7,415,000 | +16.9% | 299,356 | 0.0% | 0.09% | +12.3% | |
| THLD | Threshold Pharma | $7,232,000 | -16.8% | 1,826,358 | 0.0% | 0.09% | -19.1% | |
| SGYPQ | Synergy Pharmaceuticals | $7,156,000 | -23.4% | 1,758,271 | 0.0% | 0.09% | -26.1% | |
| IRWD | Ironwood Pharmaceuticals | $6,840,000 | +24.4% | 446,160 | 0.0% | 0.08% | +20.0% | |
| MGNX | Buy | Macrogenics, Inc. | $6,777,000 | +153.3% | 311,891 | +224.3% | 0.08% | +144.1% |
| EPZM | Epizyme Inc. | $6,660,000 | +36.7% | 214,012 | 0.0% | 0.08% | +32.3% | |
| DSCO | Discovery Laboratories Inc. | $6,501,000 | -17.2% | 3,652,117 | 0.0% | 0.08% | -20.0% | |
| ARRY | Array Biopharma Inc. | $6,538,000 | -3.0% | 1,433,797 | 0.0% | 0.08% | -7.0% | |
| TKMR | Tekmire Pharmaceuticals Corp. | $6,323,000 | -39.2% | 484,156 | 0.0% | 0.08% | -41.7% | |
| XNCR | Xencor | $6,302,000 | -0.9% | 542,363 | 0.0% | 0.08% | -4.9% | |
| INSM | Sell | Insmed Inc. | $6,075,000 | -42.4% | 304,050 | -45.1% | 0.07% | -44.8% |
| CPRX | Buy | Catalyst Pharmaceuticals, Inc. | $5,624,000 | +336.6% | 2,223,053 | +290.1% | 0.07% | +331.2% |
| NVAX | Novavax Inc. | $5,652,000 | +2.0% | 1,223,362 | 0.0% | 0.07% | -1.4% | |
| CYTR | Cytrx Corp. | $5,643,000 | +19.8% | 1,350,000 | 0.0% | 0.07% | +15.0% | |
| RXDX | Ignyta | $5,190,000 | +9.5% | 571,000 | 0.0% | 0.06% | +6.7% | |
| AMBI | Ambit Biosciences Corp. | $5,168,000 | -24.2% | 747,954 | 0.0% | 0.06% | -27.6% | |
| BDSI | BioDelivery Sciences Intl. Inc. | $5,082,000 | +43.0% | 421,005 | 0.0% | 0.06% | +37.8% | |
| STML | Stemline Therapeutics Inc. | $4,968,000 | -27.9% | 338,671 | 0.0% | 0.06% | -30.7% | |
| ZGNX | Zogenix, Inc. | $4,724,000 | -29.4% | 2,350,400 | 0.0% | 0.06% | -31.8% | |
| IDRA | Idera Pharmaceuticals Inc. | $4,678,000 | -28.9% | 1,613,076 | 0.0% | 0.06% | -32.1% | |
| LGND | Ligand Pharmaceuticals | $4,572,000 | -7.4% | 73,400 | 0.0% | 0.06% | -11.1% | |
| RARE | Ultragenyx Pharmaceuticals | $4,489,000 | -8.2% | 100,000 | 0.0% | 0.06% | -11.3% | |
| KPTI | Buy | Karyopharm Therapeutics | $4,380,000 | +140.0% | 94,095 | +59.2% | 0.05% | +134.8% |
| GALT | Sell | Galectin Therapeutics Inc. | $4,143,000 | -45.9% | 300,000 | -40.0% | 0.05% | -47.4% |
| CNCE | New | Concert Pharmaceuticals, Inc. | $4,028,000 | – | 398,800 | +100.0% | 0.05% | – |
| CLTX | Celsus Therapeuticssponsored adr ne | $3,706,000 | -15.3% | 673,887 | 0.0% | 0.04% | -19.6% | |
| ISIS | Isis Pharmaceuticals, Inc. | $3,318,000 | -20.3% | 96,303 | 0.0% | 0.04% | -22.6% | |
| ACHN | Achillion | $3,318,000 | +130.1% | 438,337 | 0.0% | 0.04% | +127.8% | |
| ENTA | Sell | Enanta Pharmaceuticals | $3,246,000 | +0.3% | 75,357 | -6.9% | 0.04% | -2.4% |
| BOTA | Biota Pharmaceuticals | $3,155,000 | -53.3% | 1,106,910 | 0.0% | 0.04% | -54.7% | |
| ALDR | New | Alder Biopharmaceuticals, Inc. | $3,078,000 | – | 153,350 | +100.0% | 0.04% | – |
| LPCN | New | Lipocine Inc. | $3,050,000 | – | 500,000 | +100.0% | 0.04% | – |
| RGDO | Regado | $2,716,000 | -45.8% | 400,000 | 0.0% | 0.03% | -48.4% | |
| MDWD | New | Mediwound Ltd. | $2,561,000 | – | 225,000 | +100.0% | 0.03% | – |
| FMI | New | Foundation Medicine Inc. | $2,107,000 | – | 78,162 | +100.0% | 0.03% | – |
| SNTA | Synta Pharmaceuticals | $2,045,000 | -5.1% | 500,000 | 0.0% | 0.02% | -7.4% | |
| LJPC | La Jolla Pharmaceuticals, Inc. | $2,035,000 | -15.0% | 221,631 | 0.0% | 0.02% | -16.7% | |
| OSUR | Orasure Technologies Inc. | $2,020,000 | +8.0% | 234,664 | 0.0% | 0.02% | +4.2% | |
| New | Mast Therapeutics, Inc. | $1,887,000 | – | 3,000,000 | +100.0% | 0.02% | – | |
| RIGL | Rigel Pharmaceuticals | $1,750,000 | -6.4% | 481,972 | 0.0% | 0.02% | -12.5% | |
| FOLD | Amicus Therapeutics | $1,609,000 | +61.4% | 481,697 | 0.0% | 0.02% | +53.8% | |
| OPHT | Ophthotech Corp. | $1,556,000 | +18.4% | 36,776 | 0.0% | 0.02% | +11.8% | |
| AKAOQ | Achaogen Inc. | $1,396,000 | -9.7% | 100,000 | 0.0% | 0.02% | -15.0% | |
| GERN | Geron Corp. | $1,292,000 | +54.4% | 402,629 | 0.0% | 0.02% | +45.5% | |
| SLXP | Buy | Salix Pharmaceuticals | $1,063,000 | +183.5% | 8,621 | +138.1% | 0.01% | +160.0% |
| ZIOP | Ziopharm Oncology Inc. | $986,000 | -12.0% | 244,619 | 0.0% | 0.01% | -14.3% | |
| TSRO | Tesaro Inc. | $971,000 | +5.5% | 31,218 | 0.0% | 0.01% | 0.0% | |
| RCPT | Receptos Inc. | $1,018,000 | +1.6% | 23,900 | 0.0% | 0.01% | -7.7% | |
| XLRN | Acceleron Pharma Inc. | $977,000 | -1.5% | 28,765 | 0.0% | 0.01% | -7.7% | |
| ALNY | Alnylam Pharmaceuticals, Inc. | $733,000 | -5.9% | 11,600 | 0.0% | 0.01% | -10.0% | |
| QURE | Uniquere B.V. | $417,000 | -12.6% | 30,672 | 0.0% | 0.01% | -16.7% | |
| CCXI | Chemocentryx Inc. | $293,000 | -11.7% | 50,000 | 0.0% | 0.00% | 0.0% | |
| FPRX | Five Prime Therapeutics Inc. | $308,000 | -21.0% | 19,823 | 0.0% | 0.00% | -20.0% | |
| CYCCP | Cyclacel Pharmaceuticals Pfd. Conv. Ex 6%pfd conv ex 6% | $108,000 | -4.4% | 13,253 | 0.0% | 0.00% | 0.0% | |
| VTUS | Exit | Ventrus Biosciences, Inc. | $0 | – | -417,690 | -100.0% | -0.01% | – |
| AUXL | Exit | Auxilium Pharmaceuticals, Inc. | $0 | – | -58,544 | -100.0% | -0.02% | – |
| MSTX | Exit | Mast Therapeutics, Inc. | $0 | – | -3,000,000 | -100.0% | -0.03% | – |
| FURX | Exit | Furiex Pharmaceuticals, Inc. | $0 | – | -40,309 | -100.0% | -0.04% | – |
| RTRX | Exit | Retrophin Inc. | $0 | – | -197,178 | -100.0% | -0.05% | – |
| PTLA | Exit | Portola Pharmaceuticals, Inc. | $0 | – | -182,591 | -100.0% | -0.06% | – |
| PRTA | Exit | Prothena Corp. PLC | $0 | – | -230,142 | -100.0% | -0.11% | – |
| CHTP | Exit | Chelsea Therapeutics | $0 | – | -6,760,394 | -100.0% | -0.47% | – |
| ICPT | Exit | Intercept Pharmaceuticals, Inc. | $0 | – | -256,375 | -100.0% | -1.08% | – |
| Exit | Auxilium 1.5% 7/15/2018conv bonds | $0 | – | -97,990,000 | -100.0% | -1.64% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-08-14
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13D/A | 2024-04-23 |
| 4 | 2024-04-22 |
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.